Immunogen (IMGN) Misses Q1 EPS by 6c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Financial Fact:
Clinical materials reimbursement: 46K
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Clinical materials reimbursement: 46K
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.30), $0.06 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $19.8 million versus the consensus estimate of $15.04 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sportradar Group AG (SRAD) Reports In-Line Q3 EPS ; Offers Guidance
- Xometry, Inc. (XMTR) Tops Q3 EPS by 9c ; Offers Guidance
- Versant Corp. (VSNT) Reports Q3 EPS of $0.34 ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
